Satellos Bioscience has concluded the enrolment of subjects for all four multiple-ascending dose (MAD) cohorts for the Phase I trial of the oral small-molecule drug SAT-3247. The drug is being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback